secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2024-06-20T23:59:59+00:00
Accession:  0001367644-24-000112
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent BioSolutions sells Baltimore-Camden facility to Bora for $30M
----------------------------------------------------------------------

- Sale of drug product facility to Bora Pharmaceuticals affiliate for total value of ~$30 million.
- Approximately 350 Emergent employees expected to join Bora as part of the transaction.
- Deal is part of multi-year plan to reduce debt, improve profitability, and streamline manufacturing to Lansing and Winnipeg.
- Closing expected in Q3 2024, subject to customary conditions; Truist Securities and Covington & Burling advised Emergent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764424000112/0001367644-24-000112-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764424000112/ebs-20240620.htm
  HTML page:      https://secwatch.observer/filing/0001367644-24-000112

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer